SCHEMBL21709455

SCHEMBL21709455

c1ccc(-c2nc(N(c3ccc(-c4cccc5c4oc4ccccc45)cc3)c3ccc(-c4cccc5c4oc4ccccc45)cc3)c3ccccc3n2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 7/20 0.48
CYP2D6 P10635 7/20 0.48
CYP3A4 P08684 6/20 0.48
CYP2C19 P33261 6/20 0.48
ALDH1A1 P00352 5/20 0.48
CYP2C9 P11712 5/20 0.48
TSHR P16473 4/20 0.48
KDM4E B2RXH2 3/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
GLA P06280 3/20 0.48
MAPT P10636 3/20 0.48
HPGD P15428 2/20 0.48
LMNA P02545 2/20 0.48
RECQL P46063 1/20 0.48
HIF1A Q16665 1/20 0.48
PDE5A O76074 3/20 0.45
ACP1 P24666 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.44
POLB P06746 1/20 0.44
ALOX5 P09917 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21709456 0.99 CYP1A2 (0.47) CYP1A2CYP2D6CYP3A4CYP2C19ALDH1A1
SCHEMBL21709278 0.91 CYP1A2 (0.42) CYP1A2CYP2D6CYP3A4CYP2C19ALDH1A1
SCHEMBL21709422 0.88 KMT2A (0.48) CYP1A2CYP2D6CYP3A4CYP2C19ALDH1A1
SCHEMBL17752686 0.87 ALOX5 (0.44) CYP1A2CYP2D6CYP3A4CYP2C19ALDH1A1
SCHEMBL17752656 0.87 ALOX5 (0.46) CYP1A2CYP2D6CYP3A4CYP2C19ALDH1A1
SCHEMBL24255927 0.84 ALOX5 (0.45) CYP1A2CYP2D6CYP3A4CYP2C19ALDH1A1
SCHEMBL17752669 0.84 ALOX5 (0.44) ALDH1A1KDM4EMAPTL3MBTL1POLB
SCHEMBL2754534 0.84 ALOX5 (0.48) ALDH1A1TSHRKDM4EGLAMAPT
SCHEMBL24255827 0.83 ALOX5 (0.44) CYP1A2CYP2D6CYP3A4CYP2C19ALDH1A1
SCHEMBL2754535 0.83 ALOX5 (0.47) ALDH1A1TSHRKDM4EGLAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200048207-A1 COMPOUNDS WITH ARYLAMINE STRUCTURES MERCK PATENT GMBH (DE) 2020-02-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200048207-A1 COMPOUNDS WITH ARYLAMINE STRUCTURES DDT, NAT1, INMT CYP1A2 64/4885CYP2D6 24/4885CYP3A4 108/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.